Farcast Biosciences.
Creating a new standard in cancer treatment decision-making.

Our revolutionary technology creates an ex vivo environment that preserves that of the human tumor microenvironment
to help reveal the most effective path forward for cancer patients, clinicians, and drug developers.

Maneesh Arora 
President & Chief Executive Officer

Maneesh most recently served as Chief Operating Officer and Director at Exact Sciences until 2018. Exact Sciences’ focus is the early detection and prevention of cancer. Exact’s lead product, Cologuard®, was developed in collaboration with the Mayo Clinic and is now widely available in the US as a frontline screening method for colorectal cancer, reimbursed by both Medicare and all major insurers. Previously, Maneesh worked for Third Wave Technologies, Inc., a molecular diagnostics company, from 2003 until its acquisition by Hologic, Inc. in July 2008. Third Wave Technologies developed an HPV product for cervical cancer screening. During his time at Third Wave, Maneesh was responsible for business strategy and commercial operations before being promoted to chief financial officer in January 2006. Maneesh earned a BA in economics from the University of Chicago and an MBA from the Kellogg School of Management at Northwestern University.

Terry Brady
Chief Financial Officer

With over 20 years of experience in finance and accounting, Terry joined Farcast in 2019. As the CFO, he leads HR, Finance, IT, Legal, and Business Analytics. His past experience includes success in public accounting, turnaround management consulting, and most recently as CFO of a large manufacturing company. He holds undergraduate and graduate degrees from the University of Notre Dame as well as an MBA from the Kellogg School of Management at Northwestern University.

JON OLINER, MD/PhD
Chief Science Officer

Dr. Jon Oliner serves as Chief Science Officer, leading the scientific organization. Jon brings over 20 years of oncology R&D experience. Most recently, Jon worked as a consultant to early-stage biopharma companies, helping them to develop and implement effective strategies for advancing their drug pipelines. Prior to that, he was a member of the Amgen Oncology senior leadership team and both founded and led Amgen’s MDM2 inhibitor and angiopoietin inhibitor programs.   Jon earned an MD/PhD from Johns Hopkins and did his graduate work in the lab of Dr. Bert Vogelstein.  He performed his postdoctoral work with Dr. Robert Tjian at UC Berkeley.

Vicki Anastasi   
Vice President, Global Clinical, Quality & Regulatory Affairs

Vicki is responsible for leading all aspects of regulatory, clinical, and quality strategy, from development to implementation. Vicki began with an education in chemistry and biochemistry from the University of Connecticut and has had a thriving career centered in regulatory and clinical affairs. Prior to Farcast, Vicki held leadership roles in the medical device industry and most recently lead the Medical Device and Diagnostics Research Business at ICON.

Parker Cassidy
Vice President, Strategy & Corporate Development

Parker leads strategic initiatives and partnerships that further the Farcast platform. He previously held senior leadership roles with Becton Dickinson and Upstate Biotechnology where he led both organic and inorganic growth initiatives. He currently serves as a Director of Qvella Corporation, Selux Diagnostics and Nanoview Biosciences. Parker received his undergraduate degree from Boston University and an MBA from the University of Virginia.

Andrea Jackson
Vice President, Sales & Marketing

Andrea serves as Vice President, Sales and Marketing, at Farcast, where she leads the commercial endeavors of the company. Prior to Farcast, Andrea held various senior leadership roles in life science startups and large companies such as PerkinElmer and Millipore, and she has launched over a dozen new scientific platforms and services. Andrea received a BA with Honors from Washington University in St. Louis and an MBA from the Kellogg School of Management at Northwestern University.